Is itching in atopic dermatitis still an unmet need? A case series of 556 patients

Tancredi, Vittorio; Licata, Gaetano; Calabrese, Giulia; Gambardella, Alessio; Rosa, Alina De; Alfano, Roberto; Argenziano, Giuseppe

doi:10.1111/jdv.18115

Cited by 3 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some studies have suggested an increased prevalence of >3% of atopic dermatitis in patients with DS 6 . Itching is the most common symptom with frequent sleep deprivation 7 . In DS, reduction of sleep hours brings to a minor attention capability and worsening of cognitive skill 8 .…”

Section: Short Clinical Case Reportsmentioning

confidence: 99%

See 1 more Smart Citation

Down syndrome and biological treatments in dermatology: Efficacy and safety in our real‐life experience and review of literature

et al. 2023

Self Cite

View full text Add to dashboard Cite

Down syndrome (DS) is the most common chromosomal disorder; several dermatological conditions are common in these patients; among them, psoriasis and atopic dermatitis can be frequently encountered. From 2017 to today, we retrospectively identified 4 adults and 3 under 18-year-old patients treated with biological drugs, from our research database. The first endpoint of this study was to evaluate whether the biological drugs work in these special population, and a secondary endpoint was to evaluate any loss of efficacy or any side effects during follow-up. All patients were treated with biological drugs experience resolution of their psoriasis. Mean PASI (Psoriasis Area Severity Index), BSA (Body Surface Area) and DLQI (Dermatology Life Quality Index) at baseline were 20, 16.5 and 25. At week 4, mean PASI, BSA and DLQI decreased, respectively, to 8, 6 and 12, while at week 24, mean values were, respectively, 3, 1.3 and 1. The patients that started therapy earlier, at week 52, do not have signs of recurrence and side effects. We highlighted that no official guidelines exist to approach these patients, from a literature evaluation the most employed drugs are anti-TNFα and in particular adalimumab. In our experience, the new anti-interleukin drugs seem to be well-tolerated, with no sides effect, good compliance and no loss of efficacy.

show abstract

Section: Short Clinical Case Reportsmentioning

confidence: 99%

“…6 Itching is the most common symptom with frequent sleep deprivation. 7 In DS, reduction of sleep hours brings to a minor attention capability and worsening of cognitive skill. 8 Anti-histaminergic drugs are commonly used to treat itching, but drowsiness is often referred.…”

Section: Short Clinical Case Reportsmentioning

confidence: 99%

Down syndrome and biological treatments in dermatology: Efficacy and safety in our real‐life experience and review of literature

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…Skin diseases, such as prurigo nodularis, nummular eczema, allergic contact dermatitis, chronic hand eczema, spontaneous chronic urticaria, bullous pemphigoid, and alopecia areata. 5 , 6 Additionally, nonskin diseases, such as asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic gastrointestinal disorders and food allergies, are new research fields. 7 , 8 Here, we describe a patient with very severe and refractory hand and foot eczema who was quickly treated with dupilumab.…”

Section: Introductionmentioning

confidence: 99%

Quick Treatment of Very Severe Refractory Hand and Foot Eczema with Dupilumab: A Case Report and Literature Review

Xiao

Sun

et al. 2023

JAA

View full text Add to dashboard Cite

Previously case reports showed dupilumab may benefit for hand eczema treatment, but relatively comprehensive assessments are lacking. A 45-year-old male with multiple severe vesicles, bullae and pustule on the palmar aspects of both hand and foot diagnosed dyshidrotic eczema by pathology was treated with dupilumab at an initial dose of 600 mg subcutaneously, followed by 300 mg every 2 weeks. The physician's assessment of the patient revealed an excellent response to the treatment with dupilumab; the lesions and symptoms achieved dramatic improvement on the third day, and at 6 weeks, the hands and feet became completely normal without relapse in the past 1.5 years of discontinuation. Systematic literature searches were performed, and 6 case reports, 5 case series, 2 prospective observational studies and 1 retrospective review with a total of 150 patients were identified to describing the evaluation of efficacy and safety of dupilumab treatment for hand and foot eczema. Dupilumab appears to be safe and well tolerated with clinical benefit in recalcitrant hand and foot eczema. Larger randomized controlled trials using validated outcome measures and detailed hand eczema type and population classification are needed before dupilumab can be applied in clinical settings.

show abstract

Ruxolitinib cream for the short-term treatment of mild-moderate atopic dermatitis

Krajewski

Szepietowski

2022

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

Is itching in atopic dermatitis still an unmet need? A case series of 556 patients

Cited by 3 publications

References 6 publications

Down syndrome and biological treatments in dermatology: Efficacy and safety in our real‐life experience and review of literature

Down syndrome and biological treatments in dermatology: Efficacy and safety in our real‐life experience and review of literature

Quick Treatment of Very Severe Refractory Hand and Foot Eczema with Dupilumab: A Case Report and Literature Review

Ruxolitinib cream for the short-term treatment of mild-moderate atopic dermatitis

Contact Info

Product

Resources

About